HPS Pharmacies wish to advise that Pfizer is experiencing a supply interruption for Heparin as follows:
Heparin sodium 5000IU/5mL
This supply interruption is expected to resolve by end-June 2023.
An internationally registered alternative has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Please note that the S19A alternative contains a preservative, while the Australian product is preservative-free.
Heparin is a high-risk medication. Additional care is recommended when selecting products, particularly when the packaging may be unfamiliar.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates